| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 12/27/2000 | EP1061940A2 Use of follistatin to modulate gdf-8 and bmp-11 |
| 12/27/2000 | EP1061937A1 Improved radiation therapy methods |
| 12/27/2000 | EP1061936A1 Cyclic dipeptides and azetidinone compounds and their use in treating cns injury and neurodegenerative disorders |
| 12/27/2000 | EP1061934A1 Fibrinogen receptor antagonists |
| 12/27/2000 | EP1061926A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists |
| 12/27/2000 | EP1061923A2 Metal chelators for use in the treatment of alzheimer's disease |
| 12/27/2000 | EP1061921A1 Vitronectin receptor antagonists |
| 12/27/2000 | EP1061919A1 Novel opiate compounds, methods of making and methods of use |
| 12/27/2000 | EP1061918A1 Controlled release composition of (1-azabicyclo(2.2.2)oct-3-yl)acetonitrile monohydrochloride |
| 12/27/2000 | EP1061917A1 Methods of inhibiting bone resorption |
| 12/27/2000 | EP1061916A2 Use os nitrone compounds for the inhibition of angiogenesis |
| 12/27/2000 | EP1061914A1 Lipoic acid analogs |
| 12/27/2000 | EP1061912A1 Phenanthrofuran derivatives |
| 12/27/2000 | EP1061911A2 Novel methods for treating disorders in which docosahexaenoic acid (dha) levels are affected |
| 12/27/2000 | EP1061910A1 Use of alpha-rar antagonists for inhibition of mucin secretion |
| 12/27/2000 | EP1061909A1 Keto acid salts and amine derivatives, and their use for preparing medicines |
| 12/27/2000 | EP1061908A1 Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
| 12/27/2000 | EP1061812A1 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 12/27/2000 | EP1061803A1 Novel compositions of eprosartan |
| 12/27/2000 | EP1061800A1 Compositions and methods for modulating vascularization |
| 12/27/2000 | EP0891322B1 Dimethyl-substituted cyclohexane diene derivatives |
| 12/27/2000 | EP0882015B1 Diphenyl stilbenes as prodrugs to cox-2 inhibitors |
| 12/27/2000 | EP0823900B1 Quinazoline derivatives |
| 12/27/2000 | EP0821671B1 Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
| 12/27/2000 | EP0821666B1 Derivatives of succinamide and their use as metalloproteinase inhibitors |
| 12/27/2000 | EP0671909B1 Syndecan stimulation of cellular differentiation |
| 12/27/2000 | CN1278255A Cyclopentene derivatives useful as antagonists of the motilin receptor |
| 12/27/2000 | CN1278252A 4,5-diaryloxazole compounds |
| 12/27/2000 | CN1278251A Novel carboxylic acid derivatives which carry amide side chains, prodn. of same, and use as endothelin receptor antagonists |
| 12/27/2000 | CN1278250A Vitronectin receptor antagonists |
| 12/27/2000 | CN1278247A Alpha-hydroxy, amino and -fluoro derivatives of beta-sulphenyl hydroxamic acids matrix metalloproteinases inhibitors |
| 12/27/2000 | CN1278245A Malonic acid based matric metalloproteinase inhibitors |
| 12/27/2000 | CN1278183A Soluble MHC complexes and methods of use thereof |
| 12/27/2000 | CN1278182A Citrus peel extract as inhibitor of acyl CoA-cholesterol-0-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall |
| 12/27/2000 | CN1278176A Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| 12/27/2000 | CN1278172A Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| 12/27/2000 | CN1278171A Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent |
| 12/27/2000 | CN1278170A Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent |
| 12/27/2000 | CN1277962A Novel substituted dipolymer compounds, prepn. method therefor, pharmaceutical compositions contg. same |
| 12/27/2000 | CN1277961A Novel 2,3-methylene amino acid compound, prepn. method therefor, pharmaceutical compositions contg. same |
| 12/27/2000 | CN1277853A Anti-fatigue farmaceutical and its prepn. process |
| 12/27/2000 | CN1059826C Traditional Chinese medicine liquor for decreasing abdomen |
| 12/27/2000 | CN1059825C Method for extracting and separating flavone and terlactone from ginkgo leaf by supercritical carbon dioxide |
| 12/27/2000 | CN1059824C Compound traditional Chinese medicine prepns. for treating silicosis, and prepn. method therefor |
| 12/27/2000 | CN1059819C Traditional Chinese medicine for reinforcing kidney and enhancing fitness of female old-aged people |
| 12/27/2000 | CN1059818C Traditional Chinese medicine preparation for invigrating brain tonifying and enhancing fitness of female teen-agers |
| 12/27/2000 | CN1059817C Traditional Chinese medicine preparation for reinforcing the kidney and enhancing fitness of old-age people |
| 12/27/2000 | CN1059816C Traditional Chinese medicine preparation for reinfocing kidney and enhancing fitness of female middle-aged persons |
| 12/27/2000 | CN1059815C Traditional Chinese medicine preparation for reinforcing the kidney and enhancing fitness of middle-aged male persons |
| 12/27/2000 | CN1059814C Traditional Chinese medicine preparation for invigorating brain and enhancing fitness of ten-agers |
| 12/26/2000 | US6166227 Preparation of (S)-2-amino-6, 6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
| 12/26/2000 | US6166221 Intermediate for 4-(hydroxy-5-(1-imidazolyl)-2-methylbenzyl)-3,5-dimethylbenzoic acid useful as a thromboxane synthetase inhibitor and an agent for the prophylaxis and treatment of diabetes |
| 12/26/2000 | US6166219 Treatment of diabetes and related disorders |
| 12/26/2000 | US6166178 Polypeptide for the treatment of cancer; anticarcinogenic agents |
| 12/26/2000 | US6166090 Prevention atherosclerosis; administering transforming growth factor |
| 12/26/2000 | US6166087 Immunosuppresants, antiinflammatory agents, antitumor agents;applying to mucous membranes |
| 12/26/2000 | US6166086 Small molecules that increase the conversion of food to body weight gain |
| 12/26/2000 | US6166084 Compositions for the treatment of chronic wounds |
| 12/26/2000 | US6166077 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 |
| 12/26/2000 | US6166074 Pharmaceutical compositions |
| 12/26/2000 | US6166063 Antidiabetic agents; antiarthritic agents; osteoporosis |
| 12/26/2000 | US6166055 Antiinflammatory agents |
| 12/26/2000 | US6166049 A treatment and/or prophylaxis of hyperglycaemia, pre-diabetic insulin resistance syndrome by administering an agonist of peroxisome proliferator-activated receptor to stimulate fatty oxidation |
| 12/26/2000 | US6166048 Pharmaceutical compositions for inhibition of cytokine production and secretion |
| 12/26/2000 | US6166046 A synergistic mix ratio |
| 12/26/2000 | US6166043 Insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin |
| 12/26/2000 | US6166042 Pharmaceutical composition |
| 12/26/2000 | US6166040 Treating a disorder of the central nervous system |
| 12/26/2000 | US6166039 Peripherally active anti-hyperalgesic opiates |
| 12/26/2000 | US6166035 1,4-dihydropyridine derivatives and their use in therapy |
| 12/26/2000 | US6166034 Spiro piperidine derivatives as 5HT1D receptor antagonists |
| 12/26/2000 | US6166030 An inhibitors of the neuronal isoform of nitric oxide synthase; treating hypoxia, stroke, ischaemia, neurodegenerative conditions, schizophrenia, pain, migraine |
| 12/26/2000 | US6166025 A stable, aqueous drug formulation for treating migraine |
| 12/26/2000 | US6166022 Treatment of platelet aggregation disorders and angina |
| 12/26/2000 | US6166020 Aryl and heteroaryl alkoxynaphthalene derivatives |
| 12/26/2000 | US6166015 Pyrrolidine derivatives-CCR-3 receptor antagonists |
| 12/26/2000 | US6166005 Heterocyclic metalloprotease inhibitors |
| 12/26/2000 | US6165999 Tetracycline derivatives |
| 12/26/2000 | US6165997 Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
| 12/26/2000 | US6165984 Administering an effective amount of naringin or naringenin to the human to prevent acylcoa-cholesterol-o-acyltransferase activity to treat hepatic diseases; inhibiting accumulation of macrophage-lipid complex on the arterial endothelium |
| 12/26/2000 | US6165983 Use of collagen for the treatment of degenerative articular processes |
| 12/26/2000 | US6165975 Microdose therapy |
| 12/26/2000 | US6165790 Antisense modulation of PI3 kinase p55 gamma expression |
| 12/26/2000 | US6165732 Drug screening by using lipid bilayer that has potassium- or chloride-selective channel formed from polpeptide of bcl-2 family, contacting compound with bilayer, and determining ion-selectivity of channel; indicates agonist or antagonist |
| 12/26/2000 | US6165720 Conjugating nucleic acid with a peptide nucleic acid in a sequence-specific manner prior to transfection, transfecting cell with conjugate, and monitoring intracellular location |
| 12/26/2000 | US6165515 Administering to the osteoporosis patient an effective amount of an extract from inflammatory tissue of rabbit skin inoculated with vaccinia virus, which is protein free hygroscopic powder, and is positive for ninhydrin reaction |
| 12/26/2000 | US6165476 Fusion proteins with an immunoglobulin hinge region linker |
| 12/26/2000 | US6165465 Immunologic enhancement of the somatogenic effect of somatotropin with an antibody |
| 12/26/2000 | US6165464 Monoclonal antibodies directed to the HER2 receptor |
| 12/26/2000 | US6165462 Sugar kinase |
| 12/26/2000 | US6165461 Tao protein kinases and methods of use therefor |
| 12/26/2000 | CA2182476C Macrocyclic difluorostatone derivatives useful as antiviral agents |
| 12/21/2000 | WO2000077256A1 48 human secreted proteins |
| 12/21/2000 | WO2000077255A1 49 human secreted proteins |
| 12/21/2000 | WO2000077246A2 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| 12/21/2000 | WO2000077237A1 49 human secreted proteins |
| 12/21/2000 | WO2000077233A2 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/21/2000 | WO2000077226A1 22025, a novel human cyclic nucleotide phosphodiesterase |
| 12/21/2000 | WO2000077210A1 Equine granulocyte-macrophage colony-stimulating factor (gm-csf) |
| 12/21/2000 | WO2000077207A2 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |